** Eye-drug maker Harrow's HROW shares rise 2.09% to $31.32
** Brokerage H.C. Wainwright starts coverage on HROW with "buy" rating; sets PT at $57
** Brokerage sees rapid growth driven by co's branded products for eye diseases
** Expects HROW to continue to make meaningful and sensible buys
** Says its eye drop Vevye compares well to other dry eye treatments
** Says that other eye products that are used during surgical procedures such as Iheezo and Triesence also serve as growth drivers
** The PT is a 84.5% upside to the stock's last close
** Stock rose ~232% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。